In a welcome move, Xenon Pharmaceuticals saw its Relative Strength Rating improve from 68 to 72 on Monday.
Can You Really Time The Stock Market?
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks compares to the rest of the market.
Over 100 years of market history reveals that the best-performing stocks typically have an RS Rating north of 80 as they launch their largest runs. See if Xenon Pharmaceuticals can continue to rebound and hit that benchmark.
While Xenon Pharmaceuticals is not near a proper buy zone right now, see if it manages to form and break out from a proper base.
Xenon Pharmaceuticals showed 0% earnings growth last quarter, while sales growth came in at -100%.
The company earns the No. 225 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
